Cargando…

Targeted therapy for metastatic renal cell carcinoma

Metastatic renal cell carcinoma (RCC) has historically been refractory to cytotoxic and hormonal agents; only interleukin 2 and interferon alpha provide response in a minority of patients. We reviewed RCC biology and explored the ways in which this understanding led to development of novel, effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, P H, Chaganti, R S K, Motzer, R J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Minireview
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361211/ https://www.ncbi.nlm.nih.gov/pubmed/16465192 http://dx.doi.org/10.1038/sj.bjc.6602978

Ejemplares similares

Sunitinib and other targeted therapies for renal cell carcinoma
por: Powles, T, et al.
Publicado: (2011)

Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma
por: Sonpavde, G, et al.
Publicado: (2012)

Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies
por: Gore, M E, et al.
Publicado: (2011)

Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma
por: Popovic, Maja, et al.
Publicado: (2022)

New perspectives on molecular targeted therapy in ovarian clear cell carcinoma
por: Tan, D S P, et al.
Publicado: (2013)

Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives
por: Pellino, Antonio, et al.
Publicado: (2019)

The place of VEGF inhibition in the current management of renal cell carcinoma
por: Nathan, P, et al.
Publicado: (2006)

Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
por: Contratto, Merly, et al.
Publicado: (2018)

Sunitinib re-challenge in advanced renal-cell carcinoma
por: Porta, C, et al.
Publicado: (2014)

Targeting HSP90 for cancer therapy
por: Mahalingam, D, et al.
Publicado: (2009)

Stem cells, quiescence and rectal carcinoma: an unexplored relationship and potential therapeutic target
por: Buczacki, S, et al.
Publicado: (2011)

Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond
por: Kudo, Masatoshi
Publicado: (2019)

Targeting TNF-α for cancer therapy
por: Burton, Elizabeth R, et al.
Publicado: (2009)

Imaging metastatic bone disease from carcinoma of the prostate
por: Messiou, C, et al.
Publicado: (2009)

The AURORA initiative for metastatic breast cancer
por: Zardavas, D, et al.
Publicado: (2014)

Role of autophagy in tumorigenesis, metastasis, targeted therapy and drug resistance of hepatocellular carcinoma
por: Huang, Fang, et al.
Publicado: (2018)

Targeting sphingosine-1-phosphate for cancer therapy
por: Sabbadini, R A
Publicado: (2006)

How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma
por: Raoul, Jean-Luc, et al.
Publicado: (2016)

Molecular therapy for the treatment of hepatocellular carcinoma
por: Greten, T F, et al.
Publicado: (2009)

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer
por: Michelakis, E D, et al.
Publicado: (2008)

Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma
por: Zheng, Lin-Lin, et al.
Publicado: (2021)

Mathematical models of targeted cancer therapy
por: Abbott, L H, et al.
Publicado: (2006)

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
por: Di Fiore, F, et al.
Publicado: (2010)

Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy
por: Zhang, Chun-Ye, et al.
Publicado: (2022)

The telomeric PARP, tankyrases, as targets for cancer therapy
por: Seimiya, H
Publicado: (2006)

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
por: Molina, Ana M., et al.
Publicado: (2010)

Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck
por: Reuter, C W M, et al.
Publicado: (2007)

Targeting mesenchymal stem cell therapy for severe pneumonia patients
por: Lam, Guy, et al.
Publicado: (2021)

Nutritional therapy for hepatocellular carcinoma
por: Ruiz-Margáin, Astrid, et al.
Publicado: (2021)

Medical nutritional therapy for renal transplantation in the COVID-19 pandemic
por: Akbulut, Gamze, et al.
Publicado: (2021)

Targets of immunotherapy for hepatocellular carcinoma: An update
por: Rai, Vikrant, et al.
Publicado: (2022)

Epigenetics in acute promyelocytic leukaemia pathogenesis and treatment response: A TRAnsition to targeted therapies
por: Arteaga, M F, et al.
Publicado: (2015)

Advancement of chimeric antigen receptor-natural killer cells targeting hepatocellular carcinoma
por: Dai, Kai, et al.
Publicado: (2021)

Neutrophil Chemokines Secreted by Tumor Cells Mount a Lung Antimetastatic Response during Renal Cell Carcinoma Progression
por: López-Lago, Miguel A., et al.
Publicado: (2012)

Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies
por: Rajkumar, Shivshankari, et al.
Publicado: (2016)

Targeting glucose metabolism for cancer therapy
por: Hamanaka, Robert B., et al.
Publicado: (2012)

Targeted Therapy for Metastatic Renal Carcinoma: an Update
por: da Silva, Rodrigo Donalisio, et al.
Publicado: (2014)

Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
por: Tsang, R Y, et al.
Publicado: (2012)

Apatinib as an alternative therapy for advanced hepatocellular carcinoma
por: Zhang, Xi-Hao, et al.
Publicado: (2020)

The epigenetic reprogramming of poorly aggressive melanoma cells by a metastatic microenvironment
por: Seftor, Elisabeth A, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_a9v2ge70ebk8m4hus2bhk1njtd